• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

    1/6/25 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GYRE alert in real time by email

    SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Group Ltd. Songjiang Ma has been appointed Chairman of the Board of Directors of Gyre Pharmaceuticals.

    Mr. Zhang has served as a Managing Partner of String Capital Management Co., Limited since 2018. Previously he was the Head of Private Equity Investment and Fund of Funds Business at AEON Life Insurance Company, Ltd. From 2011 to 2015, he served as a Managing Partner of Japan Asia Investment Co., Ltd. Prior to joining Japan Asia Investment Co., Mr. Zhang served as a Managing Director at AEA Investors LP and as a Managing Director of Mitsubishi UFJ Securities Co., Ltd. Mr. Zhang currently serves on the board of directors of GNI and Asian Star Co (TSE: 8946). He received his B.S. in Polymer Science from Fudan University and his M.B.A. in Finance from the University of Chicago Booth School of Business.

    "As we enter a potentially transformative year for the company, we are excited to welcome Mr. Zhang to our Board, where his deep financial background will prove to be invaluable, and I look forward to leveraging his insights," said Han Ying, Ph.D., CEO of Gyre Therapeutics. "I would also like to thank Dr. Luo for his leadership and contributions as Chairman of the Board. We wish him all the best in his future endeavors."

    About Gyre Therapeutics

    Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre's development strategy for F351 in MASH is based on the company's experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

    About Gyre Pharmaceuticals

    Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2023 net sales of $112.1 million). In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by early 2025. F351 received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for COPD, PAH and ALF/ACLF. In October 2023, Gyre Therapeutics acquired an indirect majority interest in Gyre Pharmaceuticals (also known as Beijing Continent Pharmaceuticals Co., Ltd.).

    For Investors:

    Stephen Jasper

    [email protected]



    Primary Logo

    Get the next $GYRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GYRE

    DatePrice TargetRatingAnalyst
    3/11/2025Outperform
    Noble Capital Markets
    More analyst ratings

    $GYRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

      SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to Gyre, before deducting the underwriting discounts and commissions and other of

      5/22/25 8:57:29 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

      SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Gyre is expected to grant the underwriters of the offering an option for a period of 30 days to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the

      5/22/25 4:02:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

      Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontinuations due to adverse events.Breakthrough Therapy Designation granted by China's National Medical Products Administration ("NMPA") in 2021 supports potential first-in-class approval in CHB-associated liver fibrosis ("CHB fibrosis").Gyre intends to seek accelerated approval for Hydronidone in CHB fibrosis, with a New Drug Application ("NDA") submission to the NMPA expected in Q3 2025. U.S. Phase 2 trial in MASH-associated liver fibrosis expected to begin in

      5/22/25 4:01:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    SEC Filings

    See more
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/23/25 4:46:36 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Gyre Therapeutics Inc.

      424B5 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/23/25 4:37:26 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Gyre Therapeutics Inc.

      424B5 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/22/25 5:27:39 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Ma Songjiang sold $44,160 worth of shares (4,000 units at $11.04) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      5/22/25 4:01:08 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $44,840 worth of shares (4,000 units at $11.21) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      5/20/25 4:01:17 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $21,586 worth of shares (2,020 units at $10.69) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      5/16/25 4:01:12 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Financials

    Live finance-specific insights

    See more
    • Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

      5/9/25 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full

      3/17/25 4:15:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

      Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f

      11/13/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Grou

      1/6/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

      SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company's Board of Directors and as a member of its Audit Committee. "Rodney has an extensive background in finance, accounting, and financial reporting with nearly four decades of experience working at global auditing and consulting firms," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies. We look forwa

      3/21/24 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:31:07 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:15:45 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Gyre Therapeutics

      Noble Capital Markets initiated coverage of Gyre Therapeutics with a rating of Outperform

      3/11/25 10:02:24 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care